Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 3, 2026Stem Cells

Mesenchymal Stem Cells and Empagliflozin: a potential therapeutic approach for autophagy and Klotho modulation in Diabetic Kidney Disease

View Full Paper
Ask AI
Bookmark
Share

Authors

MFMarcella Liciani FrancoSBStephany BeyerstedtBBBruno Sérgio Toledo Barbosa

Discussion

Loading...

Member takes

Overview

Randomized trial evaluates Klotho modulation and autophagy improvement in diabetic kidney disease, suggesting a new therapy approach.

Key Points

  • To investigate the effects of mesenchymal stem cells, empagliflozin, and calorie restriction on autophagy and Klotho modulation in diabetic kidney disease.
  • Male BTBRob/ob mice were used as a model for diabetes and diabetic kidney disease.
  • Mice were treated with MSCs, empagliflozin, and calorie restriction, then euthanized at specified weeks for analysis.
  • Kidney tissues were studied using qPCR, Western blot, and immunohistochemistry.
  • MSCs therapy improved hyperglycemia significantly (p < 0.0001).
  • There was a decrease in albuminuria and a modest improvement in eGFR (exact metrics not provided).
  • MSCs treatment modulated LC3 protein expression (p < 0.05) and maintained Klotho levels with reduced oxidative stress (p < 0.05).

Cite This Study

Franco et al. (2026) studied this question.

synapsesocial.com/papers/6a70402f75942ff7265e4fbdhttps://doi.org/10.1093/stmcls/sxag043
View Full Paper
Ask AI
Bookmark
Share